MDM2 and neoplasm: To further explore the genotype of MDM2-amplified cases and search for putative druggable targets, tumor DNA of ten cases (case #1–3 and case #5–11) was forwarded to next-generation sequencing using the OncomineTM Focus Assay, which covers hot spot mutations, copy number variations, and fusions of 52 different genes.